Health & Fitness
Health and FitnessHealth and Fitness 
Mon, April 18, 2011
XenoPort and Zalicus Poised for Growth as Earnings Trends Improve
NEW YORK, NY--(Marketwire - April 18, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on XenoPort, Inc. (
[ www.bedfordreport.com/2011-04-XNPT ]
[ www.bedfordreport.com/2011-04-ZLCS ]
IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month shares of XenoPort skyrocketed after the US Food and Drug Administration approved the company's treatment of Restless Legs Syndrome. XenoPort and its partner in commercialization, health care group GlaxoSmithKline, said the lead drug is under the trade name Horizant. XenoPort's technology modifies an existing generic drug to help patients' bodies better absorb it.
Horizant is XenoPort's first FDA approved drug, and the company faced challenges in getting FDA approval. It had to lay off about half its staff in the process.
Zalicus is a biotech firm that focuses on pain and inflammation. The company plans to advance its arthritis drug Synavive into mid-stage trials in the second quarter.
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ].